Roche: CHMP positive for Phesgo a subcutaneous fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) for HER2- positive breast cancer.-. Roche

If approved, administration of Phesgo outside of a clinical setting (such as in a person's home) by a healthcare professional will be possible, once safely established in a clinical setting. A final decision regarding the approval is expected from the European Commission in the near future.Each year, almost half a million people are diagnosed with HER2-positive breast cancer worldwide and treatment can impact a person's ability to work and contribute to society.